Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Journal of Medical Economics
|
April 6, 2013
A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden
Sten Fredrikson, Euan McLeod, Nathaniel Henry, et al.
The Cochrane Database of Systematic Reviews
|
April 26, 2017
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Graziella Filippini, Cinzia Del Giovane, Marinella Clerico, et al.
Lakartidningen
|
July 30, 2004
[A national curriculum in neurology for medical education]
Arne Lindgren, Tor Ansved, Sten-Magnus Aquilonius, et al.
CNS Drugs
|
November 25, 2016
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
Thomas Berger, Irina Elovaara, Sten Fredrikson, et al.
Neuroradiology
|
September 24, 2009
A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images
Juha Martola, Jakob Bergström, Sten Fredrikson, et al.
Lakartidningen
|
October 4, 2008
[Changing neurology--from diagnostic to therapeutic discipline]
Anja Smits, Gunnar Andsberg, Peter M Andersen, et al.
Lakartidningen
|
June 28, 2012
[The Swedish Neurological Association: The number of neurologists need to double over the next decade]
Ingela Nilsson Remahl, Sten Fredrikson, Martin Gunnarsson, et al.
Lakartidningen
|
October 4, 2008
[Representantives of the Swedish Neurological Association: Swedish neurology needs strong resource reinforcement]
Anja Smits, Peter M Andersen, Magnus Andersson, et al.
Annals of Neurology
|
February 15, 2020
Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis
Russell Ouellette, Gabriel Mangeat, Ildiko Polyak, et al.
Clinical Therapeutics
|
May 1, 2012
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis
John P Caloyeras, Bin Zhang, Cheng Wang, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Journal of Medical Economics
|
April 6, 2013
A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden
Sten Fredrikson, Euan McLeod, Nathaniel Henry, et al.
The Cochrane Database of Systematic Reviews
|
April 26, 2017
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Graziella Filippini, Cinzia Del Giovane, Marinella Clerico, et al.
Lakartidningen
|
July 30, 2004
[A national curriculum in neurology for medical education]
Arne Lindgren, Tor Ansved, Sten-Magnus Aquilonius, et al.
CNS Drugs
|
November 25, 2016
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
Thomas Berger, Irina Elovaara, Sten Fredrikson, et al.
Neuroradiology
|
September 24, 2009
A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images
Juha Martola, Jakob Bergström, Sten Fredrikson, et al.
Lakartidningen
|
October 4, 2008
[Changing neurology--from diagnostic to therapeutic discipline]
Anja Smits, Gunnar Andsberg, Peter M Andersen, et al.
Lakartidningen
|
June 28, 2012
[The Swedish Neurological Association: The number of neurologists need to double over the next decade]
Ingela Nilsson Remahl, Sten Fredrikson, Martin Gunnarsson, et al.
Lakartidningen
|
October 4, 2008
[Representantives of the Swedish Neurological Association: Swedish neurology needs strong resource reinforcement]
Anja Smits, Peter M Andersen, Magnus Andersson, et al.
Annals of Neurology
|
February 15, 2020
Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis
Russell Ouellette, Gabriel Mangeat, Ildiko Polyak, et al.
Clinical Therapeutics
|
May 1, 2012
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis
John P Caloyeras, Bin Zhang, Cheng Wang, et al.
Page
of 7